ONCYTE
OnCyte offers autologous CAR T-Cell drug candidate CM-CS1. CM-CS1 is an autologous CAR T-cell therapy which employs NKG2D, a “natural killer” cell receptor designed to target ligands present on most tumor types, including hematologic cancers as well as solid tumors. OnCyte’s portfolio also includes an allogeneic T-Cell platform designed to enable almost any CAR T-Cell therapy to be made into an “off-the-shelf” product. The platform is based on the engineering of T cells from healthy d... onors that, in addition to CAR, also express TCR Inhibitory Molecules. These molecules inhibit TCR function allowing the T cells to persist when injected into a patient. OnCyte’s CAR T-Cell technology is based on research by Charles L. Sentman, Ph.D., director of the Center for Synthetic Immunity and a professor of microbiology and immunity at Geisel School of Medicine at Dartmouth.
Similar Organizations
SaluTech
SaluTech develops a conductive biomaterial (CBM) to treat the underlying cause of arrhythmia.
More informations about "OnCyte"
onCyt Microbiology - Automated Microbial Monitoring
Founded in 2017, onCyt Microbiology AG is a spin-off of Eawag/ETH Zürich. The company emerged from a need to monitor microbes in drinking water around the clock, leading to the creation of the first fully automated online flow cytometer …See details»
Oncology & Transplant Diagnostic Solutions | Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.See details»
Our Team - Oncocyte
Josh is an experienced business leader and was previously the founder and principal of Intelliger Consulting, an organization devoted to consumer driven healthcare, and a principal at …See details»
Who We Are - Oncocyte
Unfortunately, cancer is a leading cause of death in the United States. Every year, employers, insurance companies, taxpayer-funded programs, and patients and their families spend more …See details»
Board of Directors – OncoCyte Corporation
From January 2015 to August 2020, Josh was the founder and principal of Intelliger Consulting, an organization devoted to consumer driven healthcare, and from January 2016 to July 2020, …See details»
Biopharmaceutical Company | Solutions for Unmet Medical Needs …
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..See details»
OnCyte - Crunchbase Company Profile & Funding
OnCyte’s portfolio also includes an allogeneic T-Cell platform designed to enable almost any CAR T-Cell therapy to be made into an “off-the-shelf” product. The platform is based on the …See details»
Cardio3 Acquires OnCyte CAR T-Cell Portfolio - Celdara Medical
The Company expects to report interim data from this trial throughout the enrolment period. In addition to CM-CS1, OnCyte has two CAR T-Cell programs targeting other cancer cell ligands …See details»
Serving Patients Through Innovation | Incyte Stories
At Incyte, our passion for serving patients is what drives everything we do, and we are proud to be a global organization with in-house capabilities ranging from early discovery to manufacturing …See details»
Exploring Oncyte: A Portfolio Masterpiece by Lar’Rissa Scott
Jun 23, 2024 Introduction to OncyteOncyte, a distinguished portfolio piece created by Lar'Rissa Scott, serves as a testament to her innovative vision and technical prowess. Designed to …See details»
Incyte: A Global Biopharmaceutical Company on a Mission to …
Oct 19, 2023 A: Since starting with a small team of scientists, chemists, and biologists in Wilmington, Delaware in 2002, Incyte has grown into a global organization with a robust …See details»
Celdara Medical Updates CAR-T Cell Agreement with Celyad
Celyad, a Belgium-based cell therapy company, obtained access to its CAR T cell drug product candidates and related technology in 2015 through its acquisition of OnCyte, LLC, a spin-out …See details»
Oncology Research | Targeted & Immunotherapy For Cancer - Incyte
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you are seeking medical information on our products, or wish to …See details»
Oncyte: A Portfolio Masterpiece by Lar’rissa Scott - OnCyte
Jun 23, 2024 The origins of Oncyte can be traced back to a need for a more intuitive and comprehensive platform in the healthcare technology sector. Lar'rissa Scott envisioned a …See details»
Incyte Biosciences Canada | Biopharmaceutical Company | Incyte.ca
Incyte Biosciences Canada 2600 Alfred Nobel, Suite 301 Ville St. Laurent, Quebec CANADA H4S 0A4 For general inquiries and to contact Incyte Canada, please contact …See details»
Virtici - OnCyte
Oncyte is focused on a portfolio of immuno-oncology CAR T cell therapies for cancer. Unlike traditional Chimeric Antigen Receptor (CAR) technologies, Oncyte’s therapies use the human …See details»
Cardio3 Joins CAR T-Cell Scramble with OnCyte Acquisition
Jan 6, 2015 OnCyte’s CAR T-Cell technology is based on research by Charles L. Sentman, Ph.D., director of the Center for Synthetic Immunity and a professor of microbiology and …See details»
Oncology Research | Targeted & Immuno-Therapy For Cancer
Despite progress, cancer continues to be a leading cause of death worldwide, impacting millions of people. Given the significant unmet medical need and breadth of cancers, many of which …See details»
Global Biopharmaceutical Company | Incyte.com
Since our start in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, Incyte has grown into a global organization with a robust portfolio of treatments …See details»
ONCYTE Guide to Protein Microarrays - MilliporeSigma
ONCYTE films. (B) Depiction emphasizing the advantages to spotting on a 3-dimenstional ONCYTE matrix. Scanning electron micrograph (2,000x magnification) of an ONCYTE film and …See details»